Although recent studies (Yang et al., 2016) and our study (Table S2) have shown higher expression of EZH2 in uterine fibroids, analyses of altered EZH2 expression and binding and the resulting changes in target gene expression in uterine fibroids to determine mechanisms of action and possible therapeutic potential have yet to be reported. This evidence concerns the gene EZH2 and leiomyoma.